close

Agreements

1 2 3 259
Number of results: 5179

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2019-05-21 Santhera Pharmaceuticals (Switzerland) Biozentrum, University of Basel (Switzerland) LAMA2-deficient congenital muscular dystrophy research - development - collaboration Rare diseases - Genetic diseases - Neuromuscular diseases Collaboration agreement
2019-05-21 Jacobs (USA - TX) WuXi Biologics (China) biologics drug substance manufacturing facility in Dundalk (Ireland) services contract Technology - Services Construction of new premises
2019-05-21 Wuxi Biologics (China) Wuxi Vaccines (China) undisclosed global vaccine leader construction of new premises - services contract Technology - Services - Infectious diseases Services contract
2019-05-16 Wuxi Biologics (China) integrated manufacturing center for innovative biologics construction of new premises Technology - Services Construction of new premises
2019-05-13 Oxford Genetics (UK) Cell and Gene Therapy Catapult (UK) scalable Lentiviral manufacturing processes based collaboration Technology - Services Collaboration agreement
2019-04-25 Precigen (USA-MD) opening of new premises Rare diseases - Genetic diseases - Technology - Services Opening of new premises
2019-04-24 Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA) ARO-HBV and up to three additional RNA interference (RNAi) therapeutics hepatitis B licensing - research Infectious diseases Milestone
2019-04-23 Audentes Therapeutics (USA - CA) opening of new premises Rare diseases - Genetic diseases Opening of new premises
2019-04-22 Eli Lilly (USA - IN) Avidity Biosciences (USA - CA) new medicines in immunology and other selected indications. research - licensing Immunological diseases Licensing agreement
2019-04-16 Novasep (France) Theravectys (France) DNA Flap Technology for GMP Manufacturing of lentiviral vectors licensing Technology - Services Licensing agreement
2019-04-16 Wuxi Biologics (China) I-Mab Biopharma (China) manufacturing - production Technology - Services Production agreement
2019-04-09 Wuxi Biologics (China) NBE-Therapeutics (Switzerland) NBE-002 (anti-ROR1) development - production - manufacturing Technology - Services - Cancer - Oncology Production agreement
2019-04-09 Wuxi Biologics (China) NBE-Therapeutics (Switzerland) NBE-002 (anti-ROR1) development - production - manufacturing Technology - Services - Cancer - Oncology Production agreement
2019-04-08 Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) RNAi therapeutics including ALN-AT3, fitusiran, patisiran and ALN-TTRsc02 rare genetic diseases including hemophilia A, hemophilia B development - commercialisation Rare diseases - Genetic diseases Termination of an agreement
2019-04-08 Alnylam Pharmaceuticals (USA - MA) Regeneron Pharmaceuticals (USA - NY) RNAi compounds development - commercialisation CNS diseases - Ophtalmological diseases - Liver diseases - Hepatic diseases Development agreement
2019-04-01 Avexis, a Novartis company (Switzerland) AstraZeneca (UK) biologics therapy manufacturing campus in Longmont plant acquisition Technology - Services Plant acquisition
2019-03-26 Eli Lilly (USA - IN) ImmuNext (USA - NH) preclinical novel target that could lead to potential new medicines for autoimmune diseases by regulating immune cell metabolism research - licensing Autoimmune diseases Research agreement
2019-03-25 MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) production site designed to manufacture late-stage and commercially-approved cell and gene therapy products construction of new premises Technology - Services Construction of new premises
2019-03-22 Bluebird bio (USA - MA) manufacturing facility in Durham opening of new premises Rare diseases - Genetic diseases - Technology - Services Opening of new premises
2019-03-19 Merck KGaA (Germany) GenScript (USA-NJ/China) plasmid and viral vector manufacturing collaboration Technology - Services Collaboration agreement